Skip to main content
Top
Published in: Immunologic Research 2-3/2013

01-07-2013 | Etio Pathogenesis of Autoimmunity

Adverse events following immunization with vaccines containing adjuvants

Authors: S. Cerpa-Cruz, P. Paredes-Casillas, E. Landeros Navarro, A. G. Bernard-Medina, G. Martínez-Bonilla, S. Gutiérrez-Ureña

Published in: Immunologic Research | Issue 2-3/2013

Login to get access

Abstract

A traditional infectious disease vaccine is a preparation of live attenuated, inactivated or killed pathogen that stimulates immunity. Vaccine immunologic adjuvants are compounds incorporated into vaccines to enhance immunogenicity. Adjuvants have recently been implicated in the new syndrome named ASIA autoimmune/inflammatory syndrome induced by adjuvants. The objective describes the frequencies of post-vaccination clinical syndrome induced by adjuvants. We performed a cross-sectional study; adverse event following immunization was defined as any untoward medical occurrence that follows immunization 54 days prior to the event. Data on vaccinations and other risk factors were obtained from daily epidemiologic surveillance. Descriptive statistics were done using means and standard deviation, and odds ratio adjusted for potential confounding variables was calculated with SPSS 17 software. Forty-three out of 120 patients with moderate or severe manifestations following immunization were hospitalized from 2008 to 2011. All patients fulfilled at least 2 major and 1 minor criteria suggested by Shoenfeld and Agmon–Levin for ASIA diagnosis. The most frequent clinical findings were pyrexia 68 %, arthralgias 47 %, cutaneous disorders 33 %, muscle weakness 16 % and myalgias 14 %. Three patients had diagnosis of Guillain–Barre syndrome, one patient had Adult-Still’s disease 3 days after vaccination. A total of 76 % of the events occurred in the first 3 days post-vaccination. Two patients with previous autoimmune disease showed severe adverse reactions with the reactivation of their illness. Minor local reactions were present in 49 % of patients. Vaccines containing adjuvants may be associated with an increased risk of autoimmune/inflammatory adverse events following immunization.
Literature
2.
go back to reference Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines. 2007;6(5):673–84.PubMedCrossRef Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines. 2007;6(5):673–84.PubMedCrossRef
3.
go back to reference Cruz-Tapias P, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMedCrossRef Cruz-Tapias P, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMedCrossRef
4.
go back to reference de Veer M, Meeusen E. New developments in vaccine research—unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195–204.PubMed de Veer M, Meeusen E. New developments in vaccine research—unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195–204.PubMed
6.
7.
go back to reference Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.PubMedCrossRef Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.PubMedCrossRef
8.
go back to reference WHO. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. Geneva. 1997. WHO. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. Geneva. 1997.
9.
go back to reference WHO. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva. 2000. WHO. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva. 2000.
10.
go back to reference Vitoriano-Souza J, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund’s adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.PubMedCrossRef Vitoriano-Souza J, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund’s adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.PubMedCrossRef
11.
go back to reference Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine. 2012. Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine. 2012.
12.
go back to reference Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210–6.PubMedCrossRef Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210–6.PubMedCrossRef
13.
14.
go back to reference Zafrir Y, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.PubMedCrossRef Zafrir Y, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.PubMedCrossRef
15.
go back to reference Perdan-Pirkmajer K, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus. 2012;21(2):175–83.PubMedCrossRef Perdan-Pirkmajer K, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus. 2012;21(2):175–83.PubMedCrossRef
16.
go back to reference Ray P, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011;29(38):6592–7.PubMedCrossRef Ray P, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011;29(38):6592–7.PubMedCrossRef
17.
go back to reference Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21(2):223–30.PubMedCrossRef Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21(2):223–30.PubMedCrossRef
18.
go back to reference Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99(9):1895–8.PubMedCrossRef Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99(9):1895–8.PubMedCrossRef
19.
go back to reference Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–6.PubMedCrossRef Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–6.PubMedCrossRef
20.
go back to reference Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184–9.PubMedCrossRef Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184–9.PubMedCrossRef
21.
go back to reference Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus. 2012;21(2):118–20.PubMedCrossRef Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus. 2012;21(2):118–20.PubMedCrossRef
22.
go back to reference Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103–9.PubMedCrossRef Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103–9.PubMedCrossRef
23.
go back to reference Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217–22.PubMedCrossRef Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217–22.PubMedCrossRef
24.
25.
go back to reference Barile JP, et al. Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. J Pediatr Psychol. 2012;37(1):106–18.PubMedCrossRef Barile JP, et al. Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. J Pediatr Psychol. 2012;37(1):106–18.PubMedCrossRef
26.
go back to reference Madi A. Being on the track of thimerosal. Review. Acta Microbiol Immunol Hung. 2005;52(1):95–103.PubMedCrossRef Madi A. Being on the track of thimerosal. Review. Acta Microbiol Immunol Hung. 2005;52(1):95–103.PubMedCrossRef
27.
go back to reference Barregard L, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine. Toxicol Sci. 2011;120(2):499–506.PubMedCrossRef Barregard L, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine. Toxicol Sci. 2011;120(2):499–506.PubMedCrossRef
28.
go back to reference Soriano A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21(2):153–7.PubMedCrossRef Soriano A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21(2):153–7.PubMedCrossRef
Metadata
Title
Adverse events following immunization with vaccines containing adjuvants
Authors
S. Cerpa-Cruz
P. Paredes-Casillas
E. Landeros Navarro
A. G. Bernard-Medina
G. Martínez-Bonilla
S. Gutiérrez-Ureña
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Immunologic Research / Issue 2-3/2013
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8400-4

Other articles of this Issue 2-3/2013

Immunologic Research 2-3/2013 Go to the issue

Diagnosis of Autoimmunity

Complement and autoimmunity

Treatment of Autoimmunity

Statins and autoimmunity